In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols Babesia test for samples received on April 20, 2020 at the Charlotte, Dallas, Phoenix, St. Louis and Tampa laboratories. Be watching for details on an upcoming webinar that will provide you with an overview of implementing this testing.
Check out the Communication page for the complete details by clicking the link: Communications
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...